Considerations for the safe prescribing and use of COX-2-specific inhibitors

David R. Barraclough, James V. Bertouch, Peter Brooks, Mark A. Brown, Leslie G. Cleland, Laurie E. Clemens, Steven J. Crowley, Richard O. Day, Julien P. DeJager, John P. Edmonds, Peter J. Fletcher, Gary R. Franks, David C. Harris, John D. Horowitz, Michael D. Johnston, Stephen J. Kerr, Geoff O. Littlejohn, Graham J. MacDonald, Geoff J. McColl, Phillip N. Sambrook & 3 others Sepehr Shakib, Murray W. Verso, Neville D. Yeomans

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

The majority of the "Australian COX-2-Specific Inhibitor (CSI) Prescribing Group" endorse the following points: ■ CSIs are equivalent to non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory agents. ■ CSIs and NSAIDs modify symptoms but do not alter the course of musculoskeletal disease. ■ CSIs do not eliminate the occurrence of ulcers or their serious complications, but are associated with considerably fewer peptic ulcers, slightly fewer upper GI symptoms and, according to published reports, fewer serious upper GI complications, notably bleeding, than NSAIDs. ■ CSIs and NSAIDs have similar effects on renal function and blood pressure. ■ Whether any CSI poses a risk to cardiovascular safety remains subject to debate. ■ Comorbidities and coprescribed drugs must be considered before initiating CSI (or NSAID) therapy. ■ Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy.

Original languageEnglish
Pages (from-to)328-331
Number of pages4
JournalMedical Journal of Australia
Volume176
Issue number7
Publication statusPublished - 1 Apr 2002

Cite this

Barraclough, D. R., Bertouch, J. V., Brooks, P., Brown, M. A., Cleland, L. G., Clemens, L. E., ... Yeomans, N. D. (2002). Considerations for the safe prescribing and use of COX-2-specific inhibitors. Medical Journal of Australia, 176(7), 328-331.
Barraclough, David R. ; Bertouch, James V. ; Brooks, Peter ; Brown, Mark A. ; Cleland, Leslie G. ; Clemens, Laurie E. ; Crowley, Steven J. ; Day, Richard O. ; DeJager, Julien P. ; Edmonds, John P. ; Fletcher, Peter J. ; Franks, Gary R. ; Harris, David C. ; Horowitz, John D. ; Johnston, Michael D. ; Kerr, Stephen J. ; Littlejohn, Geoff O. ; MacDonald, Graham J. ; McColl, Geoff J. ; Sambrook, Phillip N. ; Shakib, Sepehr ; Verso, Murray W. ; Yeomans, Neville D. / Considerations for the safe prescribing and use of COX-2-specific inhibitors. In: Medical Journal of Australia. 2002 ; Vol. 176, No. 7. pp. 328-331.
@article{cc0b32bc41bb4b25ae854f374e4adad6,
title = "Considerations for the safe prescribing and use of COX-2-specific inhibitors",
abstract = "The majority of the {"}Australian COX-2-Specific Inhibitor (CSI) Prescribing Group{"} endorse the following points: ■ CSIs are equivalent to non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory agents. ■ CSIs and NSAIDs modify symptoms but do not alter the course of musculoskeletal disease. ■ CSIs do not eliminate the occurrence of ulcers or their serious complications, but are associated with considerably fewer peptic ulcers, slightly fewer upper GI symptoms and, according to published reports, fewer serious upper GI complications, notably bleeding, than NSAIDs. ■ CSIs and NSAIDs have similar effects on renal function and blood pressure. ■ Whether any CSI poses a risk to cardiovascular safety remains subject to debate. ■ Comorbidities and coprescribed drugs must be considered before initiating CSI (or NSAID) therapy. ■ Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy.",
author = "Barraclough, {David R.} and Bertouch, {James V.} and Peter Brooks and Brown, {Mark A.} and Cleland, {Leslie G.} and Clemens, {Laurie E.} and Crowley, {Steven J.} and Day, {Richard O.} and DeJager, {Julien P.} and Edmonds, {John P.} and Fletcher, {Peter J.} and Franks, {Gary R.} and Harris, {David C.} and Horowitz, {John D.} and Johnston, {Michael D.} and Kerr, {Stephen J.} and Littlejohn, {Geoff O.} and MacDonald, {Graham J.} and McColl, {Geoff J.} and Sambrook, {Phillip N.} and Sepehr Shakib and Verso, {Murray W.} and Yeomans, {Neville D.}",
year = "2002",
month = "4",
day = "1",
language = "English",
volume = "176",
pages = "328--331",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "AMPCo",
number = "7",

}

Barraclough, DR, Bertouch, JV, Brooks, P, Brown, MA, Cleland, LG, Clemens, LE, Crowley, SJ, Day, RO, DeJager, JP, Edmonds, JP, Fletcher, PJ, Franks, GR, Harris, DC, Horowitz, JD, Johnston, MD, Kerr, SJ, Littlejohn, GO, MacDonald, GJ, McColl, GJ, Sambrook, PN, Shakib, S, Verso, MW & Yeomans, ND 2002, 'Considerations for the safe prescribing and use of COX-2-specific inhibitors' Medical Journal of Australia, vol. 176, no. 7, pp. 328-331.

Considerations for the safe prescribing and use of COX-2-specific inhibitors. / Barraclough, David R.; Bertouch, James V.; Brooks, Peter; Brown, Mark A.; Cleland, Leslie G.; Clemens, Laurie E.; Crowley, Steven J.; Day, Richard O.; DeJager, Julien P.; Edmonds, John P.; Fletcher, Peter J.; Franks, Gary R.; Harris, David C.; Horowitz, John D.; Johnston, Michael D.; Kerr, Stephen J.; Littlejohn, Geoff O.; MacDonald, Graham J.; McColl, Geoff J.; Sambrook, Phillip N.; Shakib, Sepehr; Verso, Murray W.; Yeomans, Neville D.

In: Medical Journal of Australia, Vol. 176, No. 7, 01.04.2002, p. 328-331.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Considerations for the safe prescribing and use of COX-2-specific inhibitors

AU - Barraclough, David R.

AU - Bertouch, James V.

AU - Brooks, Peter

AU - Brown, Mark A.

AU - Cleland, Leslie G.

AU - Clemens, Laurie E.

AU - Crowley, Steven J.

AU - Day, Richard O.

AU - DeJager, Julien P.

AU - Edmonds, John P.

AU - Fletcher, Peter J.

AU - Franks, Gary R.

AU - Harris, David C.

AU - Horowitz, John D.

AU - Johnston, Michael D.

AU - Kerr, Stephen J.

AU - Littlejohn, Geoff O.

AU - MacDonald, Graham J.

AU - McColl, Geoff J.

AU - Sambrook, Phillip N.

AU - Shakib, Sepehr

AU - Verso, Murray W.

AU - Yeomans, Neville D.

PY - 2002/4/1

Y1 - 2002/4/1

N2 - The majority of the "Australian COX-2-Specific Inhibitor (CSI) Prescribing Group" endorse the following points: ■ CSIs are equivalent to non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory agents. ■ CSIs and NSAIDs modify symptoms but do not alter the course of musculoskeletal disease. ■ CSIs do not eliminate the occurrence of ulcers or their serious complications, but are associated with considerably fewer peptic ulcers, slightly fewer upper GI symptoms and, according to published reports, fewer serious upper GI complications, notably bleeding, than NSAIDs. ■ CSIs and NSAIDs have similar effects on renal function and blood pressure. ■ Whether any CSI poses a risk to cardiovascular safety remains subject to debate. ■ Comorbidities and coprescribed drugs must be considered before initiating CSI (or NSAID) therapy. ■ Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy.

AB - The majority of the "Australian COX-2-Specific Inhibitor (CSI) Prescribing Group" endorse the following points: ■ CSIs are equivalent to non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory agents. ■ CSIs and NSAIDs modify symptoms but do not alter the course of musculoskeletal disease. ■ CSIs do not eliminate the occurrence of ulcers or their serious complications, but are associated with considerably fewer peptic ulcers, slightly fewer upper GI symptoms and, according to published reports, fewer serious upper GI complications, notably bleeding, than NSAIDs. ■ CSIs and NSAIDs have similar effects on renal function and blood pressure. ■ Whether any CSI poses a risk to cardiovascular safety remains subject to debate. ■ Comorbidities and coprescribed drugs must be considered before initiating CSI (or NSAID) therapy. ■ Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036531728&partnerID=8YFLogxK

M3 - Review Article

VL - 176

SP - 328

EP - 331

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 7

ER -

Barraclough DR, Bertouch JV, Brooks P, Brown MA, Cleland LG, Clemens LE et al. Considerations for the safe prescribing and use of COX-2-specific inhibitors. Medical Journal of Australia. 2002 Apr 1;176(7):328-331.